Riskpilot← Back to searchSign inGet full accessAlgiPharma AB
ABIn liquidationOrg 5592149826Research and experimental development on biotechnology · NACE 7211Est. 20190 employees
Revenue 2023
SEK 0
EBITDA margin
—
-17% vs 2022
Equity ratio
100.0%
Financial strength
Net profit 2023
SEK -387K
+9% vs 2022
| Revenue | SEK 0 | — |
| EBITDA | SEK -122K | -17% |
| Net profit | SEK -387K | +9% |
| Total assets | SEK 1M | -100% |
| Equity | SEK 1M | -99% |
| Employees | 0 | — |
Legal name
AlgiPharma AB
Org number
5592149826
Legal form
Aktiebolag
NACE code
7211 · Research and experimental development on biotechnology
Founded
15 augusti 2019
Share capital
SEK 1 416 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av likvidatorn likvidatorsuppleanten externa firmatecknaren
Company purpose
Bolaget ska forska, utveckla, tillverka samt sälja medicinska preparat och idka därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — |
| EBITDA | −124 | −110 | −104 | −122 |
| Depreciation & amort. | −0 | −0 | −0 | −0 |
| EBIT | −124 | −110 | −104 | −122 |
| Net financials | −122 | −516 | −320 | −265 |
| Profit before tax | −191 | −279 | −423 | −387 |
| Tax | −0 | −0 | −0 | −0 |
| Net profit | −191 | −279 | −423 | −387 |
| Item | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Total assets | 211 592 | 211 824 | 211 923 | 1 028 |
| Equity | 205 768 | 205 489 | 205 066 | 1 028 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 5 825 | 6 335 | 6 857 | 0 |
| Total debt | 5 825 | 6 335 | 6 857 | — |
EBITDA margin
-12200000.0%
This company
15.8%
Market median
-77215290% vs market
20202023
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20202023
Return on equity
-37.6%
This company
18.4%
Market median
-304% vs market
20202023
Net profit margin
-38700000.0%
This company
8.1%
Market median
-477777878% vs market
20202023
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202023
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20202023
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-08-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
JA Liquidator | Liquidator | 2024 |
AM External Signatory | External Signatory | 2024 |
WL Liquidator | Liquidator | 2024 |
ME Audit | Audit | 2024 |
AC Auditor Substitute | Auditor Substitute | 2024 |
| Former (2) | ||
YP Chief Executive Officer | Chief Executive Officer | 2020 – 2024 |
ET Chief Auditor | Chief Auditor | 2020 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Former (3) | ||
| Board of Directors | 2022 – 2024 | |
| Chairman | 2020 – 2024 | |
| Board of Directors | 2020 – 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
AlgiPharma AB (this company)
Algipharma ASBoard members of AlgiPharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jan Anders Fredrik Lovén | Liquidator | 0 companies |
| Anna Matilda Sjödin | External Signatory | 0 companies |
| Wendy Lissette Fahlgren | Liquidator | 0 companies |
| Yngvar Peter Berg | Chief Executive Officer | 0 companies |
| Mattias Eriksson | Audit | 0 companies |
| Eva Therese Kjellberg | Chief Auditor | 0 companies |
| Ann Charlott Bouvin | Auditor Substitute | 0 companies |
| Diderik Schnitler | Board of Directors | 0 companies |
| Arne Dessen | Chairman | 0 companies |
| Fredrik Veimar Alpsten | Board of Directors | 0 companies |